hepatocellar carcinoma
Conditions
Interventions
Lecithin Group:We use the emulsion which added the lecithin which is a surfactant in Lipiodol for transcatheter arterial embolization.
Non-Lecithin Group:We use the Lipiodol which didn'
t add the lecithin for transcatheter arterial embolization.
Sponsors
Women's Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1:Histologically proven or clinically diagnosed hepatocellular carcinoma in primary lesion. 2:Age20-85 3:Performance Status0-1(ECOG) 4:Life expectancy at least 3 months. 5:Adequate organ and marrow function listed below. a.White blood cell(WBC):3,000<=WBC<12,000/uL b.Absolute neutrophil count(Neu):Neu >=1,800/uL c.Hemoglobin(Hb): Hb>=8.0g/dL d.Serum creatinine(Cr):W.N.L e. Electrocardiogram(ECG):normal 6:Do not become the adaptation of resection,transplant,and local treatment in algorithm of HCC treatment. 7:Without contraindication of TAE. 8:The patient who have given written informed consent to participant in this study.
Exclusion criteria
Exclusion criteria: 1:The patient with the anamnesis of the drug hypersensitivity. 2:The patient with contraindication of medication(Hydrochloric acid doxorubicin, Lipiodol, Gelpert and lecithin). 3:The patient with contraindication of TAE. a.Severe liver failure b.Serum Bilirubin(T-Bil):T-Bil>3mg/dl c.Large quantities of acites. 4:The patient having the activity-related infectious disease(more than fever 38.0 degrees ). 5:The patient having the a serious complication. 6:Pregnant woman. 7: Patients who are judged inappropriate to be enrolled in this study by the doctor in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| curative effect,response rate,survival time, survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse events | — |
Countries
Japan
Contacts
Public ContactShun-ichi Ariizumi, Yutaka Takahashi ,
Tokyo Women's Medical University Department of Surgery, Institute of Gastroenterology
Outcome results
None listed